Research programme: K 252a derivatives - Bio3 Research/Sienna Biopharmaceuticals

Drug Profile

Research programme: K 252a derivatives - Bio3 Research/Sienna Biopharmaceuticals

Alternative Names: CT 335; CT 336; K252a derivatives

Latest Information Update: 15 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Kyowa Hakko
  • Class Antiallergics; Carbazoles
  • Mechanism of Action HMGB1 protein inhibitors; Protein tyrosine kinase inhibitors; TrkA receptor antagonists; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Behcet's syndrome; Coronary artery restenosis; Psoriasis

Most Recent Events

  • 06 Dec 2016 Creabilis Therapeutics has been acquired by Sienna Biopharmaceuticals
  • 14 Apr 2010 Discontinued - Preclinical for Behcet's syndrome in Italy (Parenteral)
  • 14 Apr 2010 Discontinued - Preclinical for Coronary artery restenosis in Italy (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top